Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 APR 6 ... and an overview of treatments. Dosing information is provided for Intron A, lamivudine, Hepsera, and Baraclude. General information is included on sales of...
2009 NOV 16 ... multi-center, randomized, double-blind Phase III clinical trials comparing Viread to Hepsera® (adefovir dipivoxil) among HBeAg-negative presumed pre-core mutant (n=375) and ...
2009 AUG 3 ... Other antiviral product sales, including Viread® (tenofovir disoproxil fumarate), Hepsera® (adefovir dipivoxil) and Emtriva® (emtricitabine), decreased six percent to ...
2009 NOV 2 ... and Europe. Other Antiviral Products Other antiviral product sales which consist of Hepsera® (adefovir dipivoxil) and Emtriva® (emtricitabine) were $74.7 million for the ...
2009 AUG 3 ... drugs should be avoided. Viread should not be administered in combination with Hepsera® (adefovir dipivoxil). Viread should only be used as part of an ...
2008 MAY 5 ... These studies evaluate the efficacy, safety and tolerability of Viread compared to Hepsera(R) (adefovir dipivoxil). Positive data from these studies were presented in late-breaker ...
2007 NOV 19 ... (November 2-6).
Studies 102 and 103 compare Viread to Gilead's Hepsera(R) (adefovir dipivoxil) among patients with HBeAg-negative (presumed pre-core mutant) ...
2008 MAY 5 ... Patients in both studies were originally randomized to receive Viread or Gilead's Hepsera(R) (adefovir dipivoxil). The studies' primary efficacy endpoints were reached at 48 ...
2008 NOV 17 ... liver disease. Patients in both studies were originally randomized to receive Viread or Hepsera(R) (adefovir dipivoxil). After the completion of 48 weeks of randomized blinded therapy, ...
2007 OCT 22 ... studies evaluate the efficacy, safety and tolerability of Viread compared to Gilead's Hepsera(R) (adefovir dipivoxil). Gilead announced the primary results from Study 102 and 103 on ...
2007 AUG 28 ... The data show that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with "e" antigen (HBeAg)-positive chronic ...
2007 NOV 5 ... Science Limited in a dispute over the distribution rights of their products Viread(TM), Hepsera(TM), Truvada(TM) and Emtriva(TM) for Switzerland.
TRB CHEMEDICA ...
2008 JUL 21 ... 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera(R) (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Pharmasset ...
2007 OCT 15 ... week treatment results, we are optimistic that clevudine will demonstrate superiority to Hepsera in its ability to suppress HBV DNA and normalize liver enzyme levels after 48 weeks of ...
